In a landmark achievement in medical science, researchers have announced a universal flu vaccine with a 95% effectiveness rate across multiple influenza strains. This breakthrough comes after years of work by an international team of virologists and immunologists who sought to end the cycle of annual flu vaccine updates. Unlike traditional vaccines that target mutable outer proteins of the virus, the new formulation focuses on the virus\'s conserved internal proteins, which mutate far less frequently.

The Phase III clinical trials involved over 30,000 participants across five continents and demonstrated high efficacy in preventing both common and emerging flu strains. Notably, it showed robust immune responses in older adults and immunocompromised individuals—groups usually at higher risk of flu complications.

Experts predict that once regulatory approvals are secured, the vaccine could be rolled out globally within two years. The World Health Organization (WHO) has hailed the development as a potential game-changer in global health, particularly in low-resource countries that struggle with consistent vaccine supply.

Healthcare providers and policymakers are now focusing on manufacturing scale-up and global distribution strategies. Public health advocates argue that the universal vaccine could dramatically reduce flu-related hospitalizations and deaths, freeing up healthcare resources for other priorities. The announcement has also sparked renewed discussions about vaccine equity and access, as international cooperation will be crucial to ensure that the new vaccine reaches populations most in need.